Zacks5d agobullish
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock UpHALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Actualités
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
53last 24h
1680last 7d
314🟢 bullish (7d)
170🔴 bearish (7d)
136publishers
Zacks5d agobullish
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts SalesBAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
Motley Fool7d agobullish
2 Dividend Stocks That Are No-Brainer Buys in MayMarkets are on the rise, but worries about a recession remain elevated as May gets underway.
Motley Fool9d agobullish
3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550These companies pay some of the world's most bankable dividends.
Motley Fool11d agobullish
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?They have combined for 118 years of consecutive dividend increases.
Motley Fool11d agobullish
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?It's hard to argue against its reliability.